VulnerabilityDeferred

CVE-2026-42933

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.

CRITICAL 10.0EPSS 0.51%

Does this matter?

High impact if exploited, but EPSS currently rates exploitation as unlikely (0.51%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.

Description

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.

CVSS 4.0: 10.0 CRITICALCVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/M
EPSS: 0.51% probability · 42th percentile
CISA KEV: Not listed
Weakness: CWE-441
Source: ics-cert@hq.dhs.gov

References

https://www.cisa.gov/news-events/ics-advisories/icsa-26-204-04

Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.